1.37
+0.08(+6.20%)
Currency In CAD
Address
9120 Leslie Street
Richmond Hill, ON L4B 3J9
Canada
Phone
905 841 2300
Sector
Healthcare
Industry
Biotechnology
Employees
7
First IPO Date
August 13, 1996
| Name | Title | Pay | Year Born |
| Mr. Jacek Antas | Chairman, Chief Executive Officer & Corporate Secretary | 100,000 | N/A |
| Dr. Jessica Kourniaktis DPHIL | Director of Communications | 0 | N/A |
| Mr. James B. Murphy | Chief Financial Officer | 0 | 1957 |
| Ms. Veronika Kandziora | Chief Operating Officer | 0 | N/A |
| Dr. Davide Guggi Ph.D. | Chief Technology Officer | 0 | N/A |
| Dr. Thomas Mehrling M.D., Ph.D. | Chief Medical Officer | 0 | N/A |
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.